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Introduction {#sec1}
============

The class I PI3K-signaling pathway is part of the large regulatory network that allows various cell surface receptors to control cell function ([@bib22], [@bib61]). This pathway plays a particularly important role in the mechanisms that allow growth factor receptors to regulate cell growth. Growth factors stimulate class I PI3Ks to catalyze the phosphorylation of the membrane lipid PI(4,5)P~2~ to form PI(3,4,5)P~3~. PI(3,4,5)P~3~ is retained in the lipid bilayer and promotes the translocation and/or activation of a variety of effectors that recognize the head group of this lipid with appropriate affinity and specificity. The best studied of these effectors are the PH domain-containing serine/threonine protein kinases PDK-1 and AKT1/2, which indirectly regulate the mTORC1 complex and promote anabolic growth and survival ([@bib9], [@bib12]). This pathway is heavily mutated in human cancers, harboring several prevalent oncogenes, including genes encoding PI3K subunits and AKT, and also several tumor suppressors, for example, PTEN and INPP4B ([@bib16], [@bib42], [@bib45], [@bib59]).

PI(3,4,5)P~3~ can be dephosphorylated by 3- and 5-phosphatases to form PI(4,5)P~2~ and PI(3,4)P~2~, respectively. The best-studied 3-phosphatase is PTEN, and loss-of-function mutants cause significant elevations in PI(3,4,5)P~3~ in various cell and animal models ([@bib26]). The major 5-phosphatases that act on PI(3,4,5)P~3~ are less clear; good evidence has been provided that SHIP1 and -2 can regulate PI(3,4,5)P~3~ levels in leukocytes and other tissues, but recent studies suggest other 5-phosphatases may also play a role, depending on cell context ([@bib11], [@bib13], [@bib46]).

The relative flux through 3- versus 5-dephosphorylation of PI(3,4,5)P~3~ is also unclear, as is the physiological significance of dephosphorylation via either route. Removal of the 5-phosphate from PI(3,4,5)P~3~ produces PI(3,4)P~2~, and recent evidence points to additional signaling roles for this lipid. PI(3,4)P~2~ can bind to some effectors with similar affinity to PI(3,4,5)P~3~, for example, AKT or DAPP1, but specific roles for this lipid have also been defined, particularly in the regulation of actin mesh-works associated with endocytic structures, lamellipodia, and podosomes/invadopodia ([@bib23], [@bib40]). Further, INPP4B has been recently identified as a conditional tumor suppressor, and a plausible mechanism of action has been constructed based on its ability to act as a specific PI(3,4)P~2~ 4-phosphatase, thus limiting the activation of AKT ([@bib14], [@bib17]).

A major problem with defining the impact of specific phosphatases in shaping the PI(3,4,5)P~3~ and PI(3,4)P~2~ signals generated by activation of class I PI3Ks is current technical limitations in their quantitative measurement. Historically, the most accurate method for measuring these lipids has been radiolabelling, lipid extraction, deacylation, and separation of the relevant head groups by anion-exchange high-performance liquid chromatography (HPLC), which is laborious, requires substantial amounts of radiolabelled precursors, and cannot be applied to tissue biopsies. Recently, we described an approach to measure PI(3,4,5)P~3~ by HPLC-mass spectrometry (MS) that circumvents many of these issues, but this method does not distinguish between regio-isomers of the same mass, for example, PI(3,4)P~2~ and PI(4,5)P~2~ ([@bib6]).

We describe here an extension to our MS method, which allows HPLC separation and measurement of PI(3,4)P~2~ and PI(4,5)P~2~. We then applied this and existing methods to execute a systematic screen for the impact of gene deletion and/or small interfering RNA (siRNA) suppression of known phosphoinositide phosphatases on shaping PI(3,4,5)P~3~ and PI(3,4)P~2~ signals in response to growth factor stimulation. These and follow-up studies led us to discover that PTEN acts as a major PI(3,4)P~2~ 3-phosphatase, in addition to its known role as a PI(3,4,5)P~3~ 3-phosphatase. Moreover, deletion of PTEN in a mouse model of prostate cancer results in very high levels of PI(3,4)P~2~ accumulation in hyperplasic epithelial cells, revealing another mechanism by which PTEN acts as a tumor suppressor.

Results {#sec2}
=======

A Method to Measure PI(3,4)P~2~ and PI(4,5)P~2~ by HPLC-MS {#sec2.1}
----------------------------------------------------------

We have previously shown that methylation of the acidic phosphate groups of polyphosphoinositides with trimethylsilyl (TMS)-diazomethane allows sensitive detection of these molecules by HPLC-electrospray ionization-mass spectrometry (HPLC-ESI-MS) ([@bib33]). This method uses reverse-phase chromatography on a C4 column, which does not allow separation of PI(3,4)P~2~ and PI(4,5)P~2~. We have now developed a modification to this method based on ozone-catalyzed cleavage of C = C double bonds to reduce acyl chain length ([Figure 1](#fig1){ref-type="fig"}A). Chromatography of these shortened derivatives on a C18-amide column yields a sufficiently good separation of molecules derived from the most common species of PI(3,4)P~2~ and PI(4,5)P~2~ found in mammalian tissues (C38:4; stearoyl/arachidonoyl) to allow an independent estimate of their relative amounts ([Figures 1](#fig1){ref-type="fig"}B and 1C). This method was able to detect PI3K-dependent accumulation of PI(3,4)P~2~ in thrombin-stimulated human platelets ([Figure 1](#fig1){ref-type="fig"}B), a response previously defined using traditional radiolabeling approaches ([@bib18], [@bib52]). Further, the routine inclusion of synthetic d6-labeled standards allowed us to accurately quantify the amounts of endogenous C38:4 PI(3,4)P~2~ and PI(4,5)P~2~ in our biological extracts ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B).Figure 1An HPLC-MS Method for Measuring PI(3,4)P~2~ and PI(4,5)P~2~(A) An illustration of the reaction of ozone with methylated stearoyl/arachidonoyl PI(4,5)P~2~.(B) HPLC-MS traces derived from human platelets, showing the separation of molecules derived from endogenous stearoyl/arachidonoyl PI(3,4)P~2~ and stearoyl/arachidonoyl PI(4,5)P~2~. Note: PI(3,5)P~2~ migrates with a slightly greater retention time than PI(4,5)P~2~ in this system, but it is present at such low endogenous levels relative to PI(4,5)P~2~ that it is below the levels of detection.(C) A typical HPLC-MS trace derived from the separation of molecules derived from chemically synthesized d6-stearoyl/arachidonoyl PI(3,4)P~2~ and d6-stearoyl/arachidonoyl PI(4,5)P~2~ added as internal standards to a human platelet cell extract.Methods: Lipid extracts were prepared, treated with TMS-diazomethane and ozone, and the resulting molecules were separated by HPLC on a C18 column, as described in the [STAR Methods](#sec4){ref-type="sec"}.Supporting information is presented in [Figure S1](#mmc1){ref-type="supplementary-material"}.

Identification of the Major Phosphatases Controlling PI(3,4,5)P~3~ and PI(3,4)P~2~ Accumulation in EGF-Stimulated Mcf10a Cells {#sec2.2}
------------------------------------------------------------------------------------------------------------------------------

We disrupted expression of phosphoinositide phosphatases in Mcf10a cells, and then we used our new and existing HPLC-MS methods to measure the effect on epidermal growth factor (EGF)-stimulated accumulation of PI(3,4,5)P~3~ and PI(3,4)P~2~. Initially, we employed an siRNA screen directed against all phosphoinositide phosphatases previously reported to act on these two lipids and expressed at significant levels in these cells (INPP5B, INPP5E, INPP5F, INPP5J, INPP5K, SHIP1, SHIP2, SYNJ1/2, OCRL, and PTEN; [@bib3], [@bib34]), and we focused on measuring PI(3,4,5)P~3~ in both starved and then EGF-stimulated wild-type (WT) cells ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We also evaluated the impact of suppressing selected phosphatases (SHIP1, SHIP2, INPP4A, and INPP4B) in a *PTEN*^−/−^ isogenic cell line (PTEN-knockout \[KO\]) ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We then followed up these initial studies by disrupting expression of INPP4B and SHIP2 in both WT and PTEN-KO cells by CRISPR/Cas9-mediated gene editing and measuring PI, PIP, PI(3,4)P~2~, PI(4,5)P~2~, and PI(3,4,5)P~3~ in selected starved and EGF-stimulated cells.

In WT cells, EGF stimulated a rapid and transient increase in the levels of PI(3,4,5)P~3~ ([Figure 2](#fig2){ref-type="fig"}A), a small transient increase in PIP ([Figure S2](#mmc1){ref-type="supplementary-material"}B), and barely detectable changes in PI(3,4)P~2~ ([Figure 2](#fig2){ref-type="fig"}B) and PI(4,5)P~2~ ([Figure 2](#fig2){ref-type="fig"}C). These responses are consistent with much previous work describing EGF stimulation of PI3Ks and PIPKs under these conditions ([@bib2], [@bib30]). The only genetic manipulations that reliably altered the PI(3,4,5)P~3~ response to EGF were knockdown (KD) or deletion of PTEN or SHIP2 ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). In each case, the effect was relatively modest, causing an ∼25%--50% increase in peak PI(3,4,5)P~3~ accumulation at 1 min. However, siRNA knockdown of SHIP2 in PTEN-KO cells or CRISPR/Cas9-mediated deletion of SHIP2 expression in PTEN-KO cells resulted in a substantial, synergistic elevation in peak PI(3,4,5)P~3~ levels (3- to 4-fold), though in each case the PI(3,4,5)P~3~ response remained transient, with levels falling within 5--15 min of EGF stimulation ([Figure 2](#fig2){ref-type="fig"}A). These results clearly identify PTEN and SHIP2 as phosphatases that act on PI(3,4,5)P~3~ during EGF stimulation, but they suggest that each can substantially compensate for loss of the other.Figure 2The Identification of Phosphatases that Shape PI(3,4,5)P~3~ and PI(3,4)P~2~ Signals in EGF-Stimulated Mcf10a Cells(A) PI(3,4,5)P~3~ levels in Mcf10a cells treated with EGF (10 ng/mL) for 0, 1, 5, or 15 min.(B) PI(3,4)P~2~ levels in Mcf10a cells treated with EGF (10 ng/mL) for 0, 1, 5, or 15 min.(C) PI(4,5)P~2~ levels in Mcf10a cells treated with EGF (10 ng/mL) for 0, 1, 5, or 15 min.Methods: Isogenic WT or *PTEN*^−/−^ Mcf10a cells were genetically manipulated through siRNA-mediated suppression or CRISPR-gene editing, as indicated, then starved and stimulated with EGF. Measurement of PI(3,4,5)P~3~ or PI(3,4)P~2~ and PI(4,5)P~2~ was performed by HPLC-MS using C4 or C18 columns, respectively, and data represent means ± SD of 3 biological replicates (for siRNA suppression in WT or PTEN-KO cells) or 3 technical replicates (for PTEN-INPP4B-KO or PTEN-SHIP2-KO cells).Supporting information is presented in [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

We also note that loss of PTEN caused an apparent drop in the levels of PI(4,5)P~2~ ([Figure 2](#fig2){ref-type="fig"}C) and a small increase in PIP ([Figure S2](#mmc1){ref-type="supplementary-material"}B). However, these changes were confined to the C38:4 species of these lipids and were not reflected in the total PIP~2~ and PIP pools (data not shown), and, therefore, they probably result from an indirect effect on acyl composition.

Combined knockdown of INPP4A and B did not produce a measurable increase in the levels of PI(3,4)P~2~ under either starved or EGF-stimulated conditions ([Figure 2](#fig2){ref-type="fig"}B). This was surprising, given that INPP4A and B are thought to be the major phosphatases controlling the levels of PI(3,4)P~2~ in mammalian cells ([@bib3]). However, knockdown of INPP4A/B in PTEN-KO cells produced a very large accumulation of PI(3,4)P~2~ in response to EGF ([Figure 2](#fig2){ref-type="fig"}B). The peak PI(3,4)P~2~ accumulation was at 5 min, reaching levels ∼10-fold greater than the peak levels of PI(3,4,5)P~3~ in the same cells and amounting to ∼20% of the total PIP~2~ pool ([Figures 2](#fig2){ref-type="fig"}A--2C).

We used CRISPR/Cas9 editing in PTEN-KO cells to eliminate expression of INPP4B. EGF stimulated very similar accumulations of PI(3,4)P~2~ in these cells compared to our analogous siRNA knockdown studies ([Figure 2](#fig2){ref-type="fig"}B). Further, siRNA knockdown of INPP4A in these cells did not increase levels of PI(3,4)P~2~ ([Figure 2](#fig2){ref-type="fig"}B), indicating INPP4B and not INPP4A was acting together with PTEN to control the levels of this lipid.

EGF-stimulated EGF receptor (EGFR) auto-phosphorylation was very similar across the relevant knockdown and knockout cell lines ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Further, we saw no evidence of compensatory increases in phosphatase expression in lines in which expression of PTEN, INPP4B, or SHIP2 had been deleted ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Interestingly, however, expression of INPP4B was significantly reduced in the PTEN-KO line ([Figure S3](#mmc1){ref-type="supplementary-material"}B), possibly contributing to the small elevation in PI(3,4)P~2~ consistently seen in these cells across multiple experiments.

PI(3,4,5)P~3~ and PI(3,4)P~2~ Accumulate in the Plasma Membrane of EGF-Stimulated Mcf10a Cells {#sec2.3}
----------------------------------------------------------------------------------------------

We used confocal fluorescence imaging with EGFP-PH-GRP1 and mCherry-PH-TAPP1 reporters to visualize the PI(3,4,5)P~3~ and PI(3,4)P~2~ pools in WT, PTEN-KO, SHIP2-KD, SHIP2-KD,PTEN-KO, and INPP4A/B-KD,PTEN-KO cells. EGF stimulated clear accumulation of the PI(3,4,5)P~3~ reporter in the proximity of the plasma membrane in all cells examined ([Figure 3](#fig3){ref-type="fig"}A), and EGF stimulated clear accumulation of the PI(3,4)P~2~ reporter in the proximity of the plasma membrane in INPP4A/B-KD,PTEN-KO cells ([Figure 3](#fig3){ref-type="fig"}B). Further, this pattern of accumulation of the PI(3,4)P~2~ reporter in these cells was confirmed by immunofluorescence using an anti-PI(3,4)P~2~ antibody ([Figure 3](#fig3){ref-type="fig"}C).Figure 3The Subcellular Location of PI(3,4,5)P~3~ and PI(3,4)P~2~ in EGF-Stimulated Mcf10a Cells(A) Confocal fluorescent images of WT or *PTEN*^−/−^ Mcf10a cells stably expressing the EGFP-GRP1-PH domain. Cells were treated with the indicated siRNA, starved, and then stimulated with EGF (10 ng/mL) for 0 or 300 s.(B) Confocal fluorescent images of WT or *PTEN*^−/−^ Mcf10a cells stably expressing the mCherry-TAPP1-PH domain. Cells were treated with the indicated siRNA, starved, and then stimulated with EGF (10 ng/mL) for 0 or 300 s.(C) Wide-field fluorescent images of WT or *PTEN*^−/−^ Mcf10a cells treated with the indicated siRNA, starved, and then stimulated with EGF (10 ng/mL) for 0 or 300 s. PI(3,4)P~2~ was visualized with an anti-PI(3,4)P~2~ antibody.

The Accumulation of PI(3,4)P~2~ in EGF-Stimulated Mcf10a Cells Is Class I PI3K Dependent {#sec2.4}
----------------------------------------------------------------------------------------

Several alternative pathways for cell surface receptor-stimulated accumulation of PI(3,4)P~2~ have been suggested, including 5-dephosphorylation of PI(3,4,5)P~3~, 3-phosphorylation of PI4P by class I PI3Ks, 3-phosphorylation of PI4P by class II PI3Ks, or sequential phosphorylation from PI3P by unidentified kinases ([@bib48], [@bib52], [@bib58]). We used a combination of experimentation and mathematical modeling to identify the major pathways that generate PI(3,4,5)P~3~ and PI(3,4)P~2~ in our system.

We first evaluated the effect of a combination of small molecule inhibitors with widely different potencies for the inhibition of class I PI3Kα/β versus class II PI3Kα/β (PIK75 and TGX115; see [Figure 4](#fig4){ref-type="fig"}A for relevant IC~50~s). These molecules inhibited the EGF-stimulated accumulation of PI(3,4,5)P~3~ and PI(3,4)P~2~ in INPP4A/B-KD,PTEN-KO cells with very similar potency ([Figure 4](#fig4){ref-type="fig"}A), suggesting both were derived from the same source and that this source was a class I PI3K. This role for a class I PI3K was supported by the sensitivity of both PI(3,4,5)P~3~ and PI(3,4)P~2~ accumulation to PI-103 and the PI3Kα-selective inhibitor BYL-719 ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). The sensitivity to BYL-719 is in agreement with previous studies indicating EGF signals primarily through PI3Kα in these cells ([@bib32]). Further, the lack of involvement of class II PI3Ks in generating PI(3,4)P~2~ responses was confirmed by siRNA knockdown of these enzymes ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D).Figure 4Evidence for Class I PI3K-Driven Accumulation of PI(3,4)P~2~ in EGF-Stimulated Mcf10a Cells(A) Measurements by HPLC-MS of PI(3,4,5)P~3~ (left panel) or PI(3,4)P~2~ (right panel) in INPP4BA/B-KD,PTEN-KO Mcf10a cells that were starved; pretreated for 20 min with the indicated dilutions of a mixture of PIK75 and TGX115 (1× represents 0.0058 μM PIK75 and 0.13 μM TGX115); and then stimulated with EGF (10 ng/mL) for 0, 1, or 5 min. Data are means ± SD of 3 technical replicates. The table shows IC~50~s of PIK75 and TGX115 against relevant PI3K activities assayed in vitro.(B) Time courses of PI(3,4,5)P~3~ (top) and PI(3,4)P~2~ (bottom) accumulation during EGF stimulation of WT, PTEN-KO, SHIP2-KD, INPP4A/B-KD, SHIP2-KD,PTEN-KO, and INPP4A/B-KD,PTEN-KO cells. Cells were starved and stimulated with EGF (10 ng/mL) at time 0. At 60 s post-EGF stimulation, samples were treated with either vehicle (DMSO; solid circles) or PI-103 (1 μM; crosses), and incubations continued for the times indicated. Data are represented as means ± SD of 3 biological replicates. Lines represent simulations of our mathematical model (see below) in the absence (continuous) or presence (dashed lines) of PI-103. Only INPP4A/B-KD,PTEN-KO cells exhibit a large increase in PI(3,4)P~2~.(C) List of biochemical reactions represented in the mathematical model, represented using Systems Biology Graphical Notation (SBGN) process descriptions ([@bib38]).(D) Simulated maximal fluxes of dephosphorylation of PI(3,4,5)P~3~ into PI(4,5)P~2~ by PTEN and into PI(3,4)P~2~ by SHIP2 and X (the combination of all other relevant 5-phosphatases). In PTEN-KO cells, all PI(3,4,5)P~3~ is converted into PI(3,4)P~2~, SHIP2 and X compensating for the absence of PTEN. In SHIP2-KD cells, while X compensates partially for the lack of SHIP2, a larger share of the fluxes is re-routed toward PI(4,5)P~2~. When both PTEN and SHIP2 are absent, the flux through X cannot fully compensate for the lack of both enzymes.(E) Simulated maximal fluxes of dephosphorylation of PI(3,4)P~2~ by INPP4B, PTEN, and an unknown phosphatase Y in WT, INPP4A/B-KD, and PTEN-KO cells. In the WT, the fluxes through INPP4B and PTEN are balanced. The fluxes are re-routed in the mutants. While an unknown phosphatase is required to accurately reproduce the experimental results, its activity remains very limited.Supporting information is presented in [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}, the [STAR Methods](#sec4){ref-type="sec"}, and [Data S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.

The identification of a class I PI3K as the source of PI(3,4)P~2~ accumulation in these experiments implied a major role for 5-phosphatase-mediated dephosphorylation of PI(3,4,5)P~3~. Surprisingly, given that we had demonstrated an involvement of SHIP2 in regulating PI(3,4,5)P~3~ levels, siRNA knockdown of INPP4A/B caused similar accumulations of PI(3,4)P~2~ in PTEN-KO cells and PTEN-KO cells in which SHIP2 expression had also been deleted by CRISPR/Cas9, though possibly with slightly slower kinetics ([Figure 2](#fig2){ref-type="fig"}B). We reasoned this may be due to redundancy among multiple PI(3,4,5)P~3~ 5-phosphatases, which could maintain flux through 5-dephosphorylation in the presence of elevated levels of PI(3,4,5)P~3~ (caused by the loss of both SHIP2 and PTEN). We therefore investigated the effect of multiple knockdowns of known 5-phosphatases in INPP4A/B-KD,PTEN-SHIP2-KO cells. Of the combinations examined, only combined knockdown of SHIP1, SYNJ1/2, INPP5F, and INPP5B caused significant elevations in PI(3,4,5)P~3~ and a modest reduction in PI(3,4)P~2~ ([Figure S4](#mmc1){ref-type="supplementary-material"}E).

It therefore remained possible that most of the PI(3,4)P~2~ produced on EGF stimulation may be derived directly by class I PI3K-mediated 3-phosphorylation of PI4P, rather than indirectly via 5-dephosphorylation of PI(3,4,5)P~3~. To estimate the flux through PI(3,4,5)P~3~ dephosphorylation, we added 1 μM PI-103 1 min after adding EGF, to prevent further activity of class I PI3K, and then we monitored the fall in PI(3,4,5)P~3~ levels ([Figure 4](#fig4){ref-type="fig"}B). PI(3,4,5)P~3~ levels dropped so quickly in WT cells that it was difficult to model the kinetics and derive an accurate rate of dephosphorylation, but the half-life was \<5 s ([Figure 4](#fig4){ref-type="fig"}B, upper left panel). Loss of PTEN, knockdown of SHIP2, and combined loss of PTEN and knockdown of SHIP2 slowed the fractional rate of PI(3,4,5)P~3~ removal, but the higher starting levels of PI(3,4,5)P~3~ maintained a high rate of PI(3,4,5)P~3~ dephosphorylation ([Figure 4](#fig4){ref-type="fig"}B, upper right panel).

We built mathematical models to test our hypotheses on PI(3,4,5)P~3~ and PI(3,4)P~2~ dephosphorylations ([Figures 4](#fig4){ref-type="fig"}C--4E; [STAR Methods](#sec4){ref-type="sec"}; [Data S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). The minimal model able to explain all of our observations includes the activation of EGFRs and the subsequent stimulation of class I PI3K activity, as well as the formation and consumption of PI(3,4,5)P~3~, PI(3,4)P~2~, PI(4,5)P~2~, PI3P, and PI4P ([Figure 4](#fig4){ref-type="fig"}C). We parameterized the model using all the time course measurements in WT, knockdown and knockout backgrounds, with and without PI3K inhibition (presence or absence of PI-103), using the genetic algorithm in COPASI software ([@bib8], [@bib44]). Parameterization of alternative models with different kinetic expressions demonstrated that the best fit to the experimental data was obtained if the assumption is made that the phosphatases involved in class I PI3K-activated phosphoinositide signaling pathways operate in their linear range, i.e., they are not saturated with their lipid substrate ([STAR Methods](#sec4){ref-type="sec"}; [Data S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). Simulations created by the operation of this model are depicted by continuous lines in [Figure 4](#fig4){ref-type="fig"}B.

The predicted ratio of flux through 5-phosphatase and 3-phosphatase attack on PI(3,4,5)P~3~ is 1.4:1, suggesting a substantial fraction of PI(3,4,5)P~3~ is recycled back to PI(4,5)P~2~ upon class I PI3K activation ([Figure 4](#fig4){ref-type="fig"}D). When PTEN is genetically deleted, this recycling is not possible and PI(3,4)P~2~ is produced at a higher rate, as a result of more PI(3,4,5)P~3~ being available to 5-phosphatases ([Figure 4](#fig4){ref-type="fig"}D). EGF-stimulated accumulation of PI(3,4)P~2~ in all mutant cells could be simulated if SHIP2 plus other 5-phosphatases (X) support PI(3,4)P~2~ production with a relative flux of ∼2.65:1 ([Figure 4](#fig4){ref-type="fig"}D). The observed level cannot be simulated if SHIP2 is the only 5-phosphatase processing PI(3,4,5)P~3~.

This model predicts that both PTEN and INPP4B directly regulate PI(3,4)P~2~ dephosphorylation, together with a further unknown phosphatase (Y). Simulations show that PTEN must act directly on PI(3,4)P~2~ and not merely increase the levels of PI(3,4,5)P~3~ and thence flux through its 5-dephosphorylation. In INPP4A/B-KD cells, all PI(3,4)P~2~ dephosphorylation flux is routed through PTEN and the unknown phosphatase Y, with a relative flux of approximately 16:1 ([Figure 4](#fig4){ref-type="fig"}E). The model predicts that Y must provide about 6% of the total PI(3,4)P~2~-phosphatase activity, based on the continued dephosphorylation of PI(3,4)P~2~ in INPP4A/B-KD,PTEN-SHIP2-KO cells in the presence of PI-103 ([Figure 4](#fig4){ref-type="fig"}B, lower right panel). Candidates for the unknown phosphatase Y are the PTEN homologs TPTE or TPIP ([@bib63]), however, there is no evidence to date that these proteins are expressed in Mcf10a cells ([@bib64]).

The model is not able to simulate the basal levels of PI(3,4)P~2~ in starved, unstimulated cells without invoking a separate pool of PI(3,4)P~2~ that is both insensitive to EGF and is not synthesized by class I PI3K (PI(3,4)P~2~\_BG; [STAR Methods](#sec4){ref-type="sec"}; [Data S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). We interrogated the nature of this EGF-insensitive pool by alternative MS analyses and \[^33^P\]-Pi-radiolabelling ([Figure S5](#mmc1){ref-type="supplementary-material"}). The results were inconclusive and it remains plausible that this pool is significantly contaminated with non-PI(3,4)P~2~-derived molecules, leading to an overestimation of the class I PI3K-insensitive pool predicted by the modeling (see the legend to [Figure S5](#mmc1){ref-type="supplementary-material"} for more detailed arguments).

PTEN Directly Dephosphorylates PI(3,4)P~2~ in Mcf10a Cytosol {#sec2.5}
------------------------------------------------------------

A clear prediction of our mathematical model is that PTEN acts as a direct PI(3,4)P~2~ phosphatase and provides around 57% of the total PI(3,4)P~2~-phosphatase activity. PTEN has previously been shown to be a poor PI(3,4)P~2~ phosphatase in assays with recombinant protein and simplified lipid substrates ([@bib43]). We re-examined the potential for PTEN to act as a PI(3,4)P~2~ phosphatase by constructing assays that were a better mimic of the physiological environment; this involved combining Mcf10a cytosol with a complex lipid substrate that contained phospholipids, cholesterol, sphingomyelin, and isotope-enriched d6-PI(3,4,5)P~3~ or d6-PI(3,4)P~2~ substrates (to avoid any ambiguity as to the origin of products derived from these substrates).

Under assay conditions resulting in less than 10% consumption of substrate, cytosol from WT cells dephosphorylated d6-PI(3,4,5)P~3~ at both 3- and 5- positions, producing d6-PI(4,5)P~2~ and d6-PI(3,4)P~2~, respectively ([Figures 5](#fig5){ref-type="fig"}A and 5B). Cytosol from PTEN-KO cells produced no significant d6-PI(4,5)P~2~, indicating PTEN is the only PI(3,4,5)P~3~ 3-phosphatase active under these conditions. Cytosol from cells lacking SHIP2 produced similar amounts of d6-PI(3,4)P~2~ to cytosol derived from cells containing SHIP2, consistent with the conclusion above that Mcf10a cells contain multiple PI(3,4,5)P~3~ 5-phosphatase activities.Figure 5Dephosphorylation of PI(3,4,5)P~3~ and PI(3,4)P~2~ by Mcf10a Cytosol(A) Measurement of 3-phosphatase activity against d6-PI(3,4,5)P~3~ present in cytosol prepared from the indicated Mcf10a cell genotypes. Data are means ± SD of 3 technical replicates.(B) Measurement of 5-phosphatase activity against d6-PI(3,4,5)P~3~ present in cytosol prepared from the indicated Mcf10a cell genotypes. Data are means ± SD of 3 technical replicates.(C) Measurement of d6-PI(3,4)P~2~-phosphatase activity present in cytosol prepared from the indicated Mcf10a cell genotypes. Data are means ± SD of 3 technical replicates.Methods: Mcf10a cytosol was prepared and incubated with liposomes containing the indicated d6-labeled phosphoinositide at 30°C, for the times indicated, and then lipids were extracted and measured by HPLC-MS, as described in the [STAR Methods](#sec4){ref-type="sec"}.Supporting information is presented in [Figure S6](#mmc1){ref-type="supplementary-material"}.

Cytosol from cells lacking INPP4B was able to dephosphorylate d6-PI(3,4)P~2~, generating d6-PIP, at a very similar rate to cytosol from WT cells ([Figure 5](#fig5){ref-type="fig"}C). Remarkably, however, cytosol from cells lacking PTEN produced no measurable d6-PIP in these assays ([Figure 5](#fig5){ref-type="fig"}C). The dephosphorylation of d6-PI(3,4)P~2~ by PTEN-KO cytosol could be rescued by the addition of catalytically active, but not catalytically dead, recombinant PTEN ([Figure S6](#mmc1){ref-type="supplementary-material"}B), demonstrating that PTEN can act as a direct PI(3,4)P~2~ phosphatase under these conditions. Further, we were able to modify our HPLC-MS method to distinguish between PI3P and PI4P (see the [STAR Methods](#sec4){ref-type="sec"}), and this was sufficient to identify the d6-PIP resulting from PTEN-dependent dephosphorylation of d6-PI(3,4)P~2~ as PI4P and, hence, define PTEN as a PI(3,4)P~2~ 3-phosphatase ([Figure S6](#mmc1){ref-type="supplementary-material"}A).

PI(3,4)P~2~ Accumulation in EGF-Stimulated Mcf10a Cells Correlates with the Activation of AKT and Increased Numbers of Invadopodia {#sec2.6}
----------------------------------------------------------------------------------------------------------------------------------

Previous work has shown deletion of PTEN or INPP4B results in hyperactivation of AKT ([@bib17]). We compared the EGF-stimulated phosphorylation of T308-AKT and S473-AKT in WT and genetically modified Mcf10a cells ([Figures 6](#fig6){ref-type="fig"}A and 6B). The knockdown of INPP4A/B or deletion of PTEN augmented the activation of AKT, and this was further increased by combined knockdown and deletion of these two enzymes ([Figures 6](#fig6){ref-type="fig"}A and 6B). The phosphorylation of AKT did not correlate closely with levels of PI(3,4)P~2~, but this might be predicted from our lack of understanding of the relative efficiency with which PI(3,4,5)P~3~ and PI(3,4)P~2~ activate AKT.Figure 6The Impact of Deleting PTEN and INPP4B on Activation of AKT and the Formation of Invadopodia in Mcf10a Cells(A and B) Phosphorylation of Thr-308-AKT (A) and Ser-473-AKT (B) in WT or PTEN-KO Mcf10a cells treated with either Ctrl or INPP4A/B siRNA and then starved and stimulated for the indicated times with EGF (0.3 ng/mL). AKT phosphorylation was measured in cell lysates after SDS-PAGE, western blotting with the relevant antibody, and then normalization against an actin loading control (see the [STAR Methods](#sec4){ref-type="sec"}). Data are means ± SD of 3 technical replicates.(C) An example of images taken of WT Mcf10a cells grown for 6 days in the presence of hTGF-β1 (10 ng/mL), plated on fluorescent gelatin for 2 hr, starved (4 hr), and then stimulated with EGF (20 ng/mL; 6 hr), before fixing and staining with an anti-cortactin antibody (see the [STAR Methods](#sec4){ref-type="sec"}). Invadopodia were identified by the co-localization of holes in the gelatin (green) with accumulations of cortactin (red; see arrows). Orthogonal projection of z stacked images shows cross-section through the gelatin surface (typically 1.5--2 μm) and invadopodia labeled with antibody against cortactin.The scale bar represents 24 μm.(D) Quantification of invadopodia formed in Mcf10a cells of the indicated genotype. The data represent means ± SD of 3 biological replicates. Statistical analysis was done using Tukey's multiple comparisons test (with p values of ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, and ^∗∗∗∗^p \< 0.0001). The effect of EGF treatment was significant in all compared genotypes.

PI(3,4)P~2~ also has a separate, specific role in mediating Tks5-dependent formation of actin-rich structures called invadopodia ([@bib55], [@bib56], [@bib67]). These structures are involved in matrix degradation and have been implicated in metastasis ([@bib39], [@bib55]). We measured the formation of invadopodia in transforming growth factor β (TGF-β)-primed Mcf10a cells grown on fluorescent-gelatin by correlating holes in the gelatin with focal accumulations of cortactin. We found that EGF stimulated a significant increase in the numbers of invadopodia and that this response was significantly augmented in cells lacking both PTEN and INPP4B ([Figures 6](#fig6){ref-type="fig"}C and 6D).

PTEN Regulates PI(3,4)P~2~ Accumulation in a Mouse Model of Prostate Cancer {#sec2.7}
---------------------------------------------------------------------------

The above studies clearly identify PTEN as a major PI(3,4)P~2~ phosphatase in vitro. To extend these observations to an in vivo context in which PTEN has been shown to play an important role, we investigated the prostate epithelial cell-specific deletion of PTEN in a mouse model of prostate cancer ([@bib60]). In the PB-Cre4 × PTEN model, expression of Cre-recombinase occurs from the onset of prostate development in newborn mice, and deletion of PTEN leads to hyperplasic growth, followed by prostate intraepithelial neoplasia (PIN) from 5 weeks and adenocarcinoma from 6 months (C. Sandi, personal communication).

We measured PI(3,4)P~2~ and PI(3,4,5)P~3~ accumulation by HPLC-MS in prostate biopsies taken from *Pten*^flox/flox^,*PbCre*^−/−^ (WT) or *Pten*^flox/flox^,*PbCre*^+/−^ (PTEN-KO) mice at 10 weeks of age ([Figures 7](#fig7){ref-type="fig"}A and 7B). We also visualized PI(3,4)P~2~ accumulation by immunofluorescence in prostate sections taken from WT or PTEN-KO mice at 12 weeks of age ([Figure 7](#fig7){ref-type="fig"}C) and sections from WT; PTEN-KO; *Pten*^flox/flox^,*PbCre*^−/−^,*Inpp4b*^−/−^ (INPP4B-KO; [@bib35]); or *Pten*^flox/flox^,*PbCre*^+/−^,*Inpp4b*^−/−^ (PTEN-INPP4B-KO) mice at 16 weeks of age ([Figures 7](#fig7){ref-type="fig"}D and 7E). Loss of PTEN alone caused a dramatic accumulation of PI(3,4)P~2~, which amounted to ∼50% of the levels of PI(4,5)P~2~ in whole-prostate biopsies ([Figures 7](#fig7){ref-type="fig"}A and 7B; luminal epithelial cells represent ∼70% of the total cells in these samples). Further, immunohistochemistry (IHC) analysis indicated preferential accumulation of PI(3,4)P~2~ in the growing tips of hyperplasic acini in sections taken from PTEN-KO and PTEN-INPP4B-KO prostates at 16 weeks ([Figure 7](#fig7){ref-type="fig"}E). PI(3,4)P~2~ accumulation also correlated closely with areas stained by an anti-phospho-S473-AKT antibody ([Figure S7](#mmc1){ref-type="supplementary-material"}A). In PTEN-KO and PTEN-INPP4B-KO prostates at 16 weeks of age, PI(3,4)P~2~ accumulation was also particularly evident in acini with surrounding sites of reactive stroma and where the smooth muscle cell layer had lost its integrity ([Figure S7](#mmc1){ref-type="supplementary-material"}B). Hence, PI(3,4)P~2~ accumulation correlated with both the earliest stages of tumor progression and later stages that constitute the first steps toward microinvasion.Figure 7The Impact of Deleting PTEN and INPP4B in Mouse Prostate(A) Measurement by HPLC-MS of the indicated phosphoinositides in prostate biopsies taken from WT or PTEN-KO mice at 10 weeks of age. Data represent means ± SD of three individual mice for each group.(B) Representative HPLC-MS chromatograms showing levels of PIP~2~ in prostate biopsies taken from WT or PTEN-KO mice at 10 weeks of age.(C) An example of Hoechst and anti-PI(3,4)P~2~-stained sections of prostates taken from WT and PTEN-KO mice at 12 weeks of age. White arrows indicate normal acini and yellow arrows indicate regions in the prostate where acini exhibit HG-PIN. Images are confocal sections of a 12-μm specimen and scale bars represent 0.2 mm.(D and E) H&E, Hoechst, and anti-PI(3,4)P~2~-stained sections of prostates taken from WT, PTEN-KO, INPP4B-KO, or PTEN-INPP4B-KO mice at 16 weeks of age (D; scale bar represents 1 mm). Some areas of PTEN-KO and PTEN-INPP4B-KO sections are shown at higher magnification (E; scale bar represents 0.2 mm), and levels of anti-PI(3,4)P~2~ staining are represented on the pseudo-color scale shown; examples of the tips of growing acini are indicated by white arrows. The images shown are typical of 3 prostate sections analyzed from 3 mice in each genotype. H&E images were stitched together using AxioVision 4 software and gaps automatically filled in using Adobe Photoshop; seminal vesicles (SV), anterior (A), dorsolateral (DLP), and ventral (V) lobes of the prostate are indicated by black arrows.(F) A representative western blot is shown describing the relative expression of INPP4B and PTEN in the indicated mouse tissues (estimated 20 μg total protein loaded per lane) and human Mcf10a cell clones (15 μg total protein loaded per lane). This experiment was repeated 3 times with similar results. Note: in PTEN-KO prostates, Cre expression and hence PTEN deletion are restricted to prostate epithelial cells, which represent only ∼70% of total cellular content.Supporting information is presented in [Figure S7](#mmc1){ref-type="supplementary-material"}.

We found no evidence for PI(3,4)P~2~ accumulation above WT in INPP4B-KO prostates and similar levels of PI(3,4)P~2~ in PTEN-KO versus INPP4B-PTEN-KO prostates ([Figures 7](#fig7){ref-type="fig"}D and [S7](#mmc1){ref-type="supplementary-material"}B). The remarkable accumulation of PI(3,4)P~2~ in mouse prostate in response to the loss of PTEN alone and the reduced contribution from INPP4B in regulating PI(3,4)P~2~ levels suggested there may be lower expression of INPP4B in mouse prostate compared to Mcf10a cells. We therefore compared the relative expression levels of PTEN and INPP4B in several mouse tissues and Mcf10a cells by western blotting. PTEN expression was similar across all samples analyzed, but expression of INPP4B was very variable, with high expression in mouse brain ([@bib15]) and Mcf10a cells but undetectable expression in WT or PTEN-KO mouse prostate ([Figure 7](#fig7){ref-type="fig"}F). The low expression of INPP4B in mouse prostate was also confirmed by RNA sequencing (RNA-seq) (C. Sandi, personal communication), and it is consistent with similar rates of prostate cancer development in PTEN single-KO and PTEN-INPP4B double-KO mice (data not shown).

PTEN Regulates PI(3,4)P~2~ Accumulation in Human Cancer Cell Lines {#sec2.8}
------------------------------------------------------------------

We measured PI(3,4)P~2~ and PI(3,4,5)P~3~ in a range of human prostate and breast cancer cells and also relative expression of INPP4B and PTEN ([Figures S7](#mmc1){ref-type="supplementary-material"}C--S7F). Loss of PTEN generally correlated with increased basal and EGF-stimulated PI(3,4,5)P~3~ responses and increased EGF-stimulated accumulation of PI(3,4)P~2~. Two exceptions were T-47D and HCC-1187, which had normal expression of PTEN but large PI(3,4,5)P~3~ responses. T-47D has previously been shown to possess an H1047 gain-of-function mutation and increased copy number of *PI3KCA* ([@bib66]). HCC-1187 has been shown to have unusually high levels of phosphorylated EGFR and platelet-derived growth factor receptor (PDGFR) ([@bib7]). The cell line with standout, selective accumulation of PI(3,4)P~2~ in response to EGF was MDA-MB-436, which lacks expression of both PTEN and INPP4B, though this was not so obvious in the two other cell lines lacking both phosphatases (BT-549 and EVSA-T). Clearly, there will be many factors at play in determining the flux through 5-dephosphorylation of PI(3,4,5)P~3~, including levels of active receptor, and thus a comparison between a relatively small number of cancer cells, with multiple differences in mutational status and gene expression, is difficult. Nevertheless, these results broadly support the idea that PTEN is likely to be a widespread regulator of PI(3,4)P~2~ levels but that this role may be more apparent in cells with reduced expression of INPP4B.

Interestingly, prostate lines lacking PTEN exhibited relatively reduced responses to IGF-1 ([Figure S7](#mmc1){ref-type="supplementary-material"}E). We suspect this is due to selective downregulation of the insulin/IGF-1/IRS-1-signaling pathway by PI3K/mTORC1-mediated feedback inhibition (T.C., unpublished data). However, the relative efficacy of different agonists to stimulate PI(3,4)P~2~ accumulation is something that clearly requires further investigation.

Discussion {#sec3}
==========

We systematically screened for phosphoinositide phosphatases in Mcf10a cells that can selectively shape the PI(3,4,5)P~3~ and PI(3,4)P~2~ signals produced in response to EGF. While our results confirm the importance of PTEN and SHIP2 as phosphatases that regulate the accumulation of PI(3,4,5)P~3~, they also point to a complex picture in these cells that is most easily explained by significant compensation among multiple phosphatases for the loss of any one individual enzyme. The extent to which these compensatory mechanisms reflect shared roles under normal conditions, are simply driven by the mass action effect of a rise in PI(3,4,5)P~3~, or depend on additional activation mechanisms is unclear. Significant redundancy among 5-phosphatases may also explain the lack of prevalent tumor suppressors among this family, though the recent identification of PIPP (INPP5J) as a potential tumor suppressor in breast cancer points to contexts in which individual enzymes may predominate ([@bib46]). We also cannot rule out that significant PI(3,4)P~2~ is produced by direct class I PI3K-catalyzed phosphorylation of PI4P, though previous studies showing analogous PI(3,4)P~2~ production lags behind that of PI(3,4,5)P~3~ ([@bib24]) and our own observations that the rate of PI(3,4,5)P~3~ degradation is sufficient to account for the rate of PI(3,4)P~2~ accumulation suggest it is not necessary to invoke this explanation.

We clearly demonstrate that PTEN is an active PI(3,4)P~2~ 3-phosphatase in Mcf10a cytosol. This is surprising given that careful in vitro studies have previously suggested that PI(3,4)P~2~ is a very poor substrate for PTEN, at least compared to PI(3,4,5)P~3~ ([@bib43]). Further, PTEN was actually a much more effective PI(3,4)P~2~ phosphatase in our assays than INPP4B, an established 4-phosphatase that is considered to catalyze the major route of PI(3,4)P~2~ dephosphorylation, to form PI3P ([@bib14], [@bib17]). Phosphoinositide-metabolizing enzymes are notoriously susceptible to in vitro assay conditions, particularly with respect to substrate presentation ([@bib29]), and we think it is probable that the use of cytosol and a complex lipid interface in our assays (which included PI(4,5)P~2~, an established co-factor for PTEN; [@bib50]) favored the detection of PTEN's PI(3,4)P~2~-phosphatase activity compared to analogous previous studies. In intact Mcf10a cells, deletion of PTEN alone had a very small impact on EGF-stimulated accumulation of PI(3,4)P~2~, and deletion of INPP4B alone had no discernible effect. However, combined deletion of PTEN and INPP4B had a very large, synergistic effect on EGF-stimulated PI(3,4)P~2~ accumulation, suggesting that in the cellular environment these two enzymes can each compensate effectively for the other's absence with respect to PI(3,4)P~2~ hydrolysis.

Our results indicate that the degree to which PI(3,4)P~2~ produced by class I PI3K at the plasma membrane can be dephosphorylated by PTEN to form PI4P has been underestimated. This conclusion is supported by studies showing overexpressed PTEN can influence PI(3,4)P~2~-reporter distributions in lymphocytes ([@bib5]), and it is also consistent with the relatively small accumulations of PI3P seen in most examples of class I PI3K activation ([@bib24], [@bib57]). It is also consistent with original observations that cell lysates can actively dephosphorylate PI(3,4)P~2~ at the 3- position ([@bib57]). It is important to note, however, that PI(3,4)P~2~ produced via different routes (e.g., class II PI3Ks) or in different locations (e.g., endosomes or clathrin-coated pits) is likely to be controlled by different phosphatases, and, at least in some of these contexts, the dephosphorylation of PI(3,4)P~2~ by INPP4A/B to form PI3P is likely to predominate ([@bib48], [@bib54]).

In mouse prostate, deleting PTEN alone had a profound effect on PI(3,4)P~2~ levels; in 10-week-old prostates the levels of PI(3,4)P~2~ rose from undetectable to approximately 50% of PI(4,5)P~2~. Deletion of INPP4B alone had an insignificant effect on PI(3,4)P~2~ accumulation, and combined deletion of INPP4B and PTEN had an insignificant impact above deletion of PTEN alone. Previous work has shown that deletion of PTEN in mouse prostate drives class I PI3K-dependent epithelial cell hyperplasia and tumor growth with 100% penetrance ([@bib31], [@bib60]), and, thus, our results represent a stunning example of how deletion of PTEN in vivo can result in massive PI(3,4)P~2~ accumulation in the context of class I PI3K pathway activation.

The lesser impact of deleting INPP4B in mouse prostate versus Mcf10a cells reflects the relative abundance of this protein in these two tissues, and it suggests that different cells and tissues may vary with respect to the relative involvement of PTEN and INPP4B in regulating PI(3,4)P~2~, a conclusion supported by our analysis of a limited collection of breast and prostate cancer cell lines. Direct evidence has been presented for a context-dependent role for INPP4B as a tumor suppressor, with deletion of *Inpp4b* driving tumor formation in mouse thyroid only in the absence of one allele of *Pten* ([@bib62]). A simple analysis of cancer genomic data using cBioPortal ([@bib4]) suggests INPP4B is not frequently mutated in human cancer and there is no striking correlation between mutation in *PTEN* and *INPP4B*. However, significant co-reductions in INPP4B and PTEN expression have been noted in human breast, ovarian, and thyroid cancers ([@bib14], [@bib17], [@bib35], [@bib62]). Further, in human prostate, INPP4B expression is regulated by androgen receptor signaling, and loss of both PTEN and INPP4B proteins is highly prevalent in castration-resistant, late-stage cancers ([@bib53], [@bib25]). Our results describing PTEN and INPP4B as PI(3,4)P~2~ 3- and 4-phosphatases, respectively, would provide a natural explanation for the impact of their combined loss in driving tumor progression.

The magnitude of EGF-stimulated PI(3,4)P~2~ accumulation in PTEN-INPP4B-KO cells suggests the flux through 5-dephosphorylation of PI(3,4,5)P~3~ is surprisingly large and that the steady-state levels of PI(3,4,5)P~3~ are dynamically regulated by very fast rates of synthesis and degradation. Whether 5-dephosphorylation brings a quantitative or qualitative element to the class I PI3K-signaling network has been debated, with strong evidence now presented for both roles ([@bib13], [@bib23], [@bib40]). The loss of INPP4B has been argued to drive increased activation of AKT through increased accumulation of PI(3,4)P~2~ ([@bib14], [@bib17]), and several PI(3,4)P~2~-selective signaling roles have also been described, for example, involving the putative PI(3,4)P~2~ effectors TAPP1/2 ([@bib10]), TKS5 ([@bib1]), SNX9 ([@bib47]), and lamellipodin ([@bib36]) in the regulation of receptor desensitization, invadopodia, endocytosis, and lamellipodia, respectively ([@bib23], [@bib40]). We present evidence that combined deletion of PTEN and INPP4B in Mcf10a cells significantly potentiates EGF-stimulated phosphorylation of AKT and also the formation of invadopodia, confirming that PI(3,4)P~2~ synthesized in this context can signal through these routes. In contrast, however, a reduction in INPP4B expression in PTEN-null breast cancer lines has recently been argued to drive PI(3,4)P~2~-dependent negative feedback, reducing activation of AKT and sensitizing cell growth to PI3Kβ inhibitors, an effect suggested to result from direct PI(3,4)P~2~-mediated inhibition of class I PI3Ks ([@bib51]). Clearly, in these cells, the impact of reducing INPP4B expression on AKT phosphorylation was the opposite to that shown here for Mcf10a cells, an untransformed breast epithelial cell line ([Figures 6](#fig6){ref-type="fig"}A and 6B). Thus, the qualitative response of a given cell to a rise in PI(3,4)P~2~ may depend exquisitely on the magnitude of this rise and the poise of the signaling pathway to respond to it.

Our results reveal an important and widespread role for PTEN as a PI(3,4)P~2~ 3-phosphatase. We think it is likely that this property of PTEN has been overlooked because of technical difficulties in measuring PI(3,4)P~2~ in cellular extracts and the properties of recombinant PTEN in the in vitro assays constructed to date. In the context of class I PI3K activation, loss of PTEN raises the levels of PI(3,4,5)P~3~, increases flux through PI(3,4,5)P~3~ 5-phosphatases, and slows dephosphorylation of the resulting PI(3,4)P~2~. In some tissues, loss of PTEN alone is sufficient to drive huge accumulations of PI(3,4)P~2~ (e.g., mouse prostate). In other cells, combined loss of both PTEN and INPP4B is required to see equivalent increases in PI(3,4)P~2~ (e.g., Mcf10a cells). These very large accumulations of PI(3,4)P~2~ will distort class I PI3K pathway signaling, through both a quantitative effect on the activation of common PI(3,4)P~2~ and PI(3,4,5)P~3~ effectors (e.g., AKT) and a signaling imbalance through the activation of PI(3,4)P~2~-selective effectors (e.g., Tks5). The effects of this distortion will be context dependent, but, for PTEN-dependent tumorigenesis and metastasis, the contribution of PI(3,4)P~2~-specific processes is clearly an area that now demands further investigation. The potential role of PTEN as a PI(3,4)P~2~ phosphatase under normal physiological conditions, within both class I and class II PI3K-signaling pathways, is also a concept that now warrants further attention.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-phospho-Akt-S473Cell SignalingD9E, 4060; RRID: [AB_2315049](nif-antibody:AB_2315049){#intref0010}Anti-phospho-Akt-T308Cell Signaling5106; RRID: [AB_836861](nif-antibody:AB_836861){#intref0015}Anti-β-COPBabraham InstituteNick KtistakisAnti-βactinAbcamAb6276; RRID: [AB_2223210](nif-antibody:AB_2223210){#intref0020}Anti-INPP4ASanta CruzSc-12314; RRID: [AB_2126009](nif-antibody:AB_2126009){#intref0025}Anti-INPP4BSanta CruzSc-12318; RRID: [AB_2126126](nif-antibody:AB_2126126){#intref0030}Anti-SHIP1Cell Signaling2728; RRID: [AB_2126244](nif-antibody:AB_2126244){#intref0035}Anti-PTENCell Signaling9188; RRID: [AB_2253290](nif-antibody:AB_2253290){#intref0040}Anti-EGFRCell Signaling4267; RRID: [AB_2246311](nif-antibody:AB_2246311){#intref0045}Anti-phospho-EGFRCell Signaling3777; RRID: [AB_2096270](nif-antibody:AB_2096270){#intref0050}Anti-CortactinAbcamAb33333; RRID: [AB_731713](nif-antibody:AB_731713){#intref0055}Biotinylated anti-PI(3,4)P2Echelon Biosciencesz-B034b; RRID: [AB_427214](nif-antibody:AB_427214){#intref0060}Alexa 568 goat anti-mouseLife TechnologiesA11004; RRID: [AB_2534072](nif-antibody:AB_2534072){#intref0065}Alexa 568 goat anti-RabbitLife TechnologiesA11036; RRID: [AB_10563566](nif-antibody:AB_10563566){#intref0070}Alexa 647 goat anti-mouseLife TechnologiesA21235; RRID: [AB_2535804](nif-antibody:AB_2535804){#intref0075}Alexa 647 goat anti-RabbitLife TechnologiesA21244; RRID: [AB_10562581](nif-antibody:AB_10562581){#intref0080}Steptavidin-Alexa 647Life TechnologiesS32357IRdye 680 goat anti-Rabbit IgGLI-COR926-68071; RRID: [AB_10956166](nif-antibody:AB_10956166){#intref0085}IRdye 800 goat anti-mouse IgGLI-COR926-32210; RRID: [AB_621842](nif-antibody:AB_621842){#intref0090}Goat anti-mouse antibody HRPBio-Rad170-6516; RRID: [AB_11125547](nif-antibody:AB_11125547){#intref0095}Goat anti-Rabbit antibody HRPBio-Rad170-6515; RRID: [AB_11125142](nif-antibody:AB_11125142){#intref0100}Anti-SHIP2Cell Signaling2730; RRID: [AB_659982](nif-antibody:AB_659982){#intref0105}**Biological Samples**Human PlateletsDr Ingeborg HersUniversity of Bristol**Chemicals, Peptides, and Recombinant Proteins**TMS-diazomethaneSigma-Aldrich362832Fatty acid free BSASigma-AldrichA7906Dulbecco's phosphate buffered salineSigma-AldrichD8537Human insulinSigma-AldrichI9278Human EGFSigma-AldrichE9644HydrocortisoneSigma-AldrichH0888PBS10xLife Technologies70011-036DMEM/F12Life Technologies31330-038RPMI-1640Sigma-AldrichR8758Insulin-Transferrin-SeleniumThermo Fisher Scientific41400045DihydrotestosteroneSigma-AldrichD-073-1MLFetal Bovine SerumThermo Fisher Scientific10270106Distilled waterLife Technologies15230-089rhTGF-β1R&D Systems240-BGelatin from pig skin- Oregon Green 488Fisher Scientific11594856\[33\]P-γATPPerkinElmerNEG602H250UCBYL719Biochem InhibitorA-1214d6-C18:0/C20:4-PI(3,4,5)P3Synthesized by the Biological Chemistry Department in Babraham InstituteContact Jonathan Clark1-heptadecanoyl-2-hexadecanoyl-sn-glycero-3- (phosphoinositol 3,4,5-trisphosphate) (C17:0/C16:0-PI(3,4,5)P3)Synthesized by the Biological Chemistry Department in Babraham InstituteContact Jonathan ClarkC17:0/C16:0-PISynthesized by the Biological Chemistry Department in Babraham InstituteContact Jonathan Clarkd6- C18:0/C20:4-PI(3)PSynthesized by the Biological Chemistry Department in Babraham InstituteContact Jonathan Clarkd6-C18:0/C20:4-PI(4)PSynthesized by the Biological Chemistry Department in Babraham InstituteContact Jonathan Clarkd6-C18:0/C20:4-PI(3,4)P2Synthesized by the Biological Chemistry Department in Babraham InstituteContact Jonathan Clarkd6-C18:0/C20:4- PI(4,5)P2Synthesized by the Biological Chemistry Department in Babraham InstituteContact Jonathan ClarkC18:0/C20:4-PI(3,4)P2Synthesized by the Biological Chemistry Department in Babraham InstituteContact Jonathan ClarkC18:0/C20:4 PI(3,5)P2Synthesized by the Biological Chemistry Department in Babraham InstituteContact Jonathan ClarkC18:0/C20:4 PI(4,5)P2Synthesized by the Biological Chemistry Department in Babraham InstituteContact Jonathan ClarkC18:0/C20:4 PI(3,4,5)P3Synthesized by the Biological Chemistry Department in Babraham InstituteContact Jonathan ClarkC17:0/C20:4-PIAvanti Polar LipidsLM-1502Horse serumPAAB15-021Penicillin/streptomycinLife Technologies15140-122CS-FBSLife Technologies12676-029Cholera toxinSigma-AldrichC8052DharamaFECT1GE DharmaconT-2001-04OptimemLife Technologies31985-047Lipofectamine 2000Invitrogen11668-019Polybrene used at 4 μg/mLSigma-AldrichTR-1003-GTrisMelfordB2005NaClVWR Chemicals27810.295EDTASigma-AldrichE5134EGTASigma-AldrichE4378TritonSigma-AldrichT9284Anti-protease leupeptinSigma-AldrichL8511Anti-protease AprotininSigma-AldrichA1153Anti-protease antipainSigma-AldrichA6191Anti-protease pepstatinSigma-AldrichP5318PMSFSigma-Aldrich78830Na4P2O7Sigma-AldrichP8010β- glycerolphosphateCalbiochem35675Na3VO4Sigma-AldrichS6508NaFSigma-AldrichS7920PVDF membranes (immobilon P)MilliporeIPVH00010DTTMelfordMB1015Tris-HClSigma-AldrichT3253GlycerolInvitrogen15514-011Bromophenol BlueSigma-AldrichB8026MethanolRomilH410ChloroformRomilH140AcetoneVWR chemicals20066.330Dimethyl sulphideSigma-Aldrich34869Formic acidFisher ScientificF/1900/PB08AcetonitrileRomilM050HEPESSigma-AldrichH3375MgCl2VWR Chemicals25108.295Protease inhibitor cocktailRoche11836170001Bovin Serum AlbuminSigma-AldrichA7906KClVWR Chemicals26764.260Trichloroacetic acid 6.1NSigma-AldrichT0699Embedding mediumThermo Scientific1310Mayer's hematoxylin solutionSigma-AldrichSLBP6175VEosin Y solutionSigma-AldrichSLBP1949V**Critical Commercial Assays**AMAXA nucleofection systemLonzaKit TLasky ozone generatorAirTree Ozon technologyC-L010-DT**Deposited Data**Original Images deposited at Mendeley DataMendeley Data<https://doi.org/10.17632/tnj6m88k6w.1>**Experimental Models: Cell Lines**PTEN^−/−^ and Parental Mcf10aHorizon DiscoveryHD101-006**Experimental Models: Organisms/Strains**PB-Cre4 miceJAXStrain 026662PTENloxP/loxP miceJAXStrain 004597'WT' (PTEN^loxP/loxP^, PbCre^−/−^) miceThis paperN/A'PTEN-KO' (PTEN^loxP/loxP^, PbCre^+/−^) miceThis paperN/AINPP4B^−/−^ mice[@bib35]N/ABPH-1DSMZACC143DU-145Dr Scholesex Tenovus InstitutePC-3ATCCCRL 1435EVSA-TDSMZACC 433LnCAP-95Dr MeekerJohn Hopkins UniversityT47DATCCHTB 133LnCAPATCCCRL 1740CAL-120DSMZACC 459BT-549ATCCHTB 122MDA-MB-436ATCCHTB 130HCC-70ATCCCRL 2315HCC-1937ATCCCRL 2336MDA-MB-157ATCCHTB 24HCC-1187ATCCCRL 2322**Oligonucleotides**INPP4B knockout sgRNAdesigned by <https://chopchop.rc.fas.harvard.edu>5′-GATCTCCGTAATCCACCCCG-3′SHIP2 knockout sgRNAdesigned by <https://chopchop.rc.fas.harvard.edu>5′- GTGCAGGCCTTTGAGGTACA-3′**Recombinant DNA**pSpCas9(BB)-2A-GFPAddgene48138pMIGR1-mCherry-PH-TAPPThis paperN/AGFP-GRP1-PH domain[@bib21]N/APLVX-IRES-Puro VectorClontech632183**Software and Algorithms**FIJINIHN/APrismGraphPadN/AImarisBitplaneN/ACOPASI[@bib27]N/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Phillip Hawkins (<phillip.hawkins@babraham.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

PB-Cre4 mice ([@bib65]) and PTEN^loxP/loxP^ mice ([@bib60]) have been described previously. PbCre4 mice and PTEN^loxP/loxP^ mice were interbred to generate 'WT' (PTEN^loxP/loxP^, PbCre^−/−^) and 'PTEN-KO' (PTEN^loxP/loxP^, PbCre^+/−^) mice and backcrossed to the C57BL/6J strain for at least 4 generations; these mice were housed in the Biological Support Unit at The Babraham Institute. INPP4B^−/−^ mice have been described previously ([@bib35]) and were interbred with PTEN-KO mice to generate 'PTEN-INPP4B-KO' (PTEN^loxP/loxP^, PbCre^+/−^, INPP4B^−/−^) mice; these mice were housed in the Akita University Animal House.

#### Sample Size Estimation {#sec4.3.1.1}

No estimation of simple size was performed as sample sizes were not chosen based on pre-specified effect size. Instead, multiple independent experiments were carried out using several biological replicates specified in the legends to figures.

#### How Subjects/Samples Were Allocated to Experimental Groups {#sec4.3.1.2}

Prostates from several age-matched mice of identical genotype were analyzed.

#### Gender of Subjects or Animals {#sec4.3.1.3}

Male mice were used.

#### Health/Immune Status {#sec4.3.1.4}

The animals were kept under SPF conditions and the animal facilities where the mice were kept were regularly checked for standard pathogens. Health reports can be provided upon request.

#### Whether Subjects Were Involved in Previous Procedures {#sec4.3.1.5}

Prostates were prepared from mice not subject to any previous experimentation.

#### Whether the Subject Is Drug or Test Naive {#sec4.3.1.6}

Mice used for all experiments were naive. No drug tests were done.

#### Husbandry Conditions of Experimental Animals {#sec4.3.1.7}

All animal experiments at The Babraham Insitute were reviewed and approved by The Animal Welfare and Ethics Review Body and performed under Home Office Project license PPL 70/8100. Animal experiments in Akita were reviewed and approved by the Akita University Institutional Committee for Animal Studies, Akita University. The mice were looked after by professional caretakers. Every animal was checked daily.

#### Housing Conditions of Experimental Animals {#sec4.3.1.8}

Animals housed in the Biological Support Unit at the Babraham Institute were kept under specific pathogen--free conditions. Mice in the animal facility in Akita were kept in groups of up to six animals in standard IVC cages of 524 cm^2^ containing bedding and nesting material. Food and water was provided ad libitum. The light cycle ran from 6 am to 6 pm.

### Cell Lines {#sec4.3.2}

Mcf10a cells are non-transformed human female breast epithelial cells. PTEN^−/−^ Mcf10a cell lines were generated by targeted homologous recombination and were obtained from Horizon Discovery Ltd together with their parental cell lines. All Mcf10a cell lines were maintained at 37°C with 5% CO~2~ in DMEM/F12 supplemented with 5% horse serum, 10 ng/mL EGF, 10 μg/mL insulin, 0.1 μg/mL cholera toxin, 0.5 μg/mL hydrocortisone, 1% w/v penicillin/streptomycin (complete medium). Starvation medium consisted of DMEM/F12 supplemented with 1% charcoal/dextran treated fetal bovine serum, 0.1 μg/mL cholera toxin, 0.5 μg/mL hydrocortisone, 1% P/S.

Human prostate cancer cells (DU-145, BPH-1, LNCaP, LNCaP 95 and PC-3) and breast cancer cells (T-47D, EVSA-T, CAL-120, BT-549, MDA-MB-436, HCC70, HCC-1187, HCC-1937, MDA-MB-157) were obtained from the AstraZeneca cell bank and had been previously authenticated using DNA fingerprinting short tandem repeat assays. All revived cells were used within 10 passages and cultured at 37°C with 5% CO2 for less than 2 months. Benign prostatic hyperplasia epithelial cell line BPH-1 was cultured in RPMI-1640 supplemented with 20% FBS, 10 μg/mL insulin, 6.7 ng/mL sodium selenite, 5.5 μg/mL transferrin, 0.5 nM dihydrotestosterone and 1% w/v penicillin/streptomycin. The remaining prostate and breast cancer cell lines were grown in RPMI-1640 with 10% FBS and 1% w/v penicillin/streptomycin.

### Human Tissue (Platelets) {#sec4.3.3}

Venous blood was obtained from a healthy female human volunteer with the approval of the local research ethics committee at the University of Bristol, UK. The donor provided written informed consent, and reported as not having taken medication in the 14 days prior to donation. Blood was drawn into 4% trisodium citrate (1:9, v/v), and acidified with acidic citrate dextrose (1:7, v/v; 120 mM sodium citrate, 110 mM glucose, 80 mM citric acid). Platelet-rich plasma (PRP) was obtained by centrifugation of the blood at 180xg for 17 min at room temperature. Platelets were subsequently pelleted by centrifugation of the PRP at 650 x g for 10 min at room temperature in the presence of 10 μM indomethacin and 0.02 U/mL apyrase (grade VII). Platelets were resuspended at 4 × 10^8^/mL in HEPES--Tyrode buffer (145 mM NaCl, 3 mM KCl, 0.5 mM Na~2~HPO~4~, 1 mM MgS0~4~.7H~2~O, 10 mM HEPES, pH 7.2) supplemented with 0.1% \[w/v\] D-glucose, 10 μM indomethacin and 0.02 U/mL apyrase, and allowed to rest at 30°C for 30 min prior to experimentation.

Method Details {#sec4.4}
--------------

### Preparation of Platelets for PI(3,4)P~2~ Measurement {#sec4.4.1}

1 × 10^8^ platelets were preincubated with DMSO or 100 nM Wortmannin for 10 min, before treatment with HEPES--Tyrode buffer or 0.5 U/mL thrombin for 3 min under stirring at 1200 r.p.m using a Chronolog 490-4D aggregometer at 37°C (Labmedics, Abingdon-on-Thames, UK). Treatment was stopped by the addition of 750 μl ice-cold 1 M HCl and samples were centrifuged at 12000 x g for 10 min at 4°C. Resulting pellets were frozen until lipid extraction.

### siRNA Suppression {#sec4.4.2}

1.6 × 10^5^ cells were seeded per 35 mm dish, and were subject to reverse transfection (using transfection agent DharamaFECT1) with a pool of 4 different siRNA (40 nM per target; ON-Target-plus pooled siRNA.) in Optimem and 10% complete medium, according to manufacturer's instructions. Media was changed after 16 hr and replaced with complete medium for 32 hr, after which cells were washed with dPBS and maintained in starvation media for 16 hr. Cells were stimulated with 10 ng/mL of EGF for the indicated times. Where indicated, cells were pre-incubated with inhibitors for 20 min prior to EGF stimulation. Stimulations were terminated by aspiration of media and washing with ice-cold PBS, prior to processing of the cells for lipid or western blot analysis as described below.

### Gene Editing of Mcf10a Cell Lines Using CRISPR/Cas9 {#sec4.4.3}

sgRNAs were designed using <https://chopchop.rc.fas.harvard.edu/> or <http://crispr.mit.edu/> and cloned into all-in-one pSpCas9(BB)-2A-GFP plasmid, plasmid as described previously ([@bib49]). To generate an INPP4B knockout, sgRNA 5′- GATCTCCGTAATCCACCCCG-3′ targeting exon 7 was used. SHIP2 knockout was generated using sgRNA 5′-GTGCAGGCCTTTGAGGTACA-3′ directed against exon 8. Mcf10a cells were transfected with 4 μg DNA using the AMAXA nucleofection system. After 24-48 hr, GFP positive cells were FACS sorted and seeded at the density of up to 1 cell per well in a 96 well plate using a conditioned medium (1:1 mix of fresh Mcf10a medium and conditioned medium harvested after 3 days in culture with Mcf10a cells and 0.45 μm filtered). Single clones were picked after 7 days, expanded, and analyzed for loss of protein by western blot using anti-INPP4B and anti-SHIP2 antibodies.

### Generation of Mcf10a Cells Stably Expressing Fluorescent Reporters {#sec4.4.4}

The GFP-PH-GRP1 domain construct was kindly provided by Guillaume Halet ([@bib21]). This construct incorporates a nuclear export signal resulting in the exclusion of GFP-PH-GRP1 from the nucleus, and was subcloned into PLVX-IRES-Puro Vector. The generation of Lentivirus as well as the transduction of Mcf10A cells were performed according to the manufacturer's guidelines.

mCherry-PH-TAPP1 expressing Mcf10a cells were generated using the isolated PH domain of TAPP1 cloned into the retroviral vector pMIGR1, previously modified to introduce mCherry fluorescent protein cDNA upstream of the multiple cloning site (pMIGR1-mCherry). Retrovirus was generated by transfecting 10 μg pMIGR1-mCherry-PH-TAPP into amphotropic phoenix cells (maintained in DMEM supplemented with 10% FBS, 1% penicillin/streptomycin in 37°C humidified incubator) using lipofectamine 2000, according to the manufacturer instructions. Following 24 hr incubation, media was replaced with complete Mcf10a medium and incubated at 32°C for a further 24 hr. Retroviral containing media was then collected and passed through a 0.45 μm filter, before adding to WT or PTEN^−/−^ Mcf10a cells, as indicated, cultured in 6 well dishes. Cells were incubated at 32°C for a further 4 hr in the presence of 4 μg/mL polybrene before transferring to 37°C. Cells were expended and washed several times in complete Mcf10a media before a mixed population of mCherry-PH-TAPP1 expressing cells were used for image analysis as described below.

### Western Blot {#sec4.4.5}

#### Mcf10a {#sec4.4.5.1}

Cells were scraped and lysed in 150 μL of ice-cold lysis buffer (20 mM Tris, pH 7.5; 150 mM NaCl; 1 mM EDTA, pH 7.5; 1 mM EGTA, pH 7.5; 0.1% v/v Triton X-100 supplemented with anti-proteases: 10 μg/mL leupeptin, 10 μg/mL aprotinin, 10 μg/mL antipain, 10 μg/mL pepstatin A, 0.1 mM PMSF and anti-phosphatases: 2.5 mM Na~4~P~2~O~7~, 5 mM β- glycerophosphate, 1 mM Na~3~VO~4~, 25 mM NaF). After 30 min solubilisation at 4°C with agitation, lysates were centrifuged (15,000 x g, 10 min, 4°C) and the supernatants collected and diluted in SDS-PAGE sample buffer. Proteins (45 μg/well, or 15 μg/well, where indicated) were resolved on a SDS-PAGE gel, transferred to PVDF membranes and blotted with the indicated primary antibodies at 4°C overnight. They were then washed in TBS (40 mM Tris/HCl, pH 8.0, 22°C; 0.14 M, NaCl) containing 0.1% v/v Tween 20 and incubated with a mix of Infrared Dye coupled secondary antibodies. The membranes were imaged with the Li-Cor Odyssey Infrared Imaging System using the 700 nm and 800 nm channels. Signals were quantified using the Image Studio software. Alternatively, membranes were washed and incubated with HRP-conjugated secondary antibodies and signals detected using the ECL detection system. Signals from the HRP-incubated membranes were quantified using Aida software.

#### Mouse Tissues {#sec4.4.5.2}

Tissues were pulverized under a continuous flow of N~2(l)~. 1x reducing SDS sample buffer (0.1 M DTT, 40 mM Tris-HCl pH 6.7, 12.5% glycerol, 0.003% Bromophenol Blue) was pre-warmed to 70°C and 750 μL of sample buffer was added per 50 mg tissue to yield an approximate final protein concentration of 4 mg/mL. Lysates were homogenized by vortexing for 15 s followed by a sequential syringe step through a 21G needle (3x), followed by a 23G needle (3x). Proteins were denatured by boiling at 95°C for 5 min. Lysates were cleared by centrifugation for 5 min at 20,238 x g, after which the syringe and centrifugation steps were repeated. Proteins were resolved by SDS-PAGE (20 μg estimated total protein per lane) and immunoblotted for the indicated antibodies.

### Lipid Extraction {#sec4.4.6}

750,000 Mcf10a cells grown on a 35 mm dish were killed in 750 μL ice-cold 1 M HCL, then scraped and collected into an Eppendorf tube. Each sample was then split into three separate 2 mL polypropylene Eppendorf tubes; 250 μL for PI, PIP, PIP~2~, PIP~3~ measurement, 250 μL for PI(3,4)P~2~/PI(4,5)P~2~ measurement, and the remaining cells were kept for analysis by western blot. Cells were pelleted in a microfuge (15,000 x g, 10 min at 4°C), the supernatant removed and cell pellets either processed immediately or snap-frozen in liquid nitrogen and stored at −80°C for up to two weeks.

For human prostate and breast cancer cell lines, 250,000 cells were seeded into 35 mm dishes and grown in the medium optimal for each cell line for 32h. Cells were then starved for 16h by replacing the medium with starvation medium -- a phenol red-free RPMI 1640 supplemented with 2mM glutamax. Following stimulation and / or inhibition with appropriate reagents, medium was removed by aspiration and cells killed with 750 μl ice-cold 1M HCL. Cells were then scraped, collected into Eppendorf tubes, pelleted, and snap-frozen, as described above.

920 μL of a solvent mixture containing 2:1:0.79 (v/v) MeOH:CHCl~3~:H~2~O~(acidic)~ was added to the cell pellets and the mixture vortexed thoroughly for 10 s. Relevant internal standards were then added:10 ng C17:0/C16:0-PIP~3~, 100 ng C17:0/C16:0-PI, 250 ng d6-C18:0/C20:4-PI(4,5)P~2~ for routine analysis of PI, PIP, PIP~2~ and PIP~3~; 50 ng C17:0/C20:4 PI, 50 ng d6- C18:0/C20:4-PI(3,4)P~2~, 250 ng d6-C18:0/C20:4-PI(4,5)P~2~ for routine analysis of PI, PI(3,4)P~2~ and PI(4,5)P~2~. Lipids were then extracted using an acidified Folch phase partition and derivatised with TMS-diazomethane ([@bib6]).

Molecules derived from PI, PIP, PIP~2~, and PIP~3~ were measured by HPLC-MS ([@bib33]). Response ratios were calculated for the endogenous species of these lipids divided by their relevant C17:0/C16:0 internal standard. We routinely analyzed 5 molecular species of these lipids but present here data for the C38:4 species only, to align with data presented for the C38:4 species of PI(3,4)P~2~ and PI(4,5)P~2~ (see below). The C38:4 species of PIP~2~ and PIP~3~ represent approx. 10%--15% of the total species of these lipids in Mcf10a cells and all species behave very similarly upon stimulation with EGF ([@bib2]). In some experiments, absolute amounts of C38:4 PI(3,4,5)P~3~ were generated by reference to standard curves previously generated for this molecular species ([@bib33]). Three technical replicates were routinely analyzed for each experiment and, unless stated otherwise, data are presented as means SD of three biological replicates.

Molecules derived from PI, PI(3,4)P~2~ and PI(4,5)P~2~ were analyzed by a new HPLC-MS method, see below. Response ratios were calculated for the endogenous C38:4 species of these lipids divided by their relevant d6-labeled internal standard. In some experiments, absolute amounts of these lipids were generated by reference to standard curves ([Figure S1](#mmc1){ref-type="supplementary-material"}). Three technical replicates were routinely analyzed for each experiment and, unless stated otherwise, data are presented as means SD of three biological replicates.

### Measurement of PI(3,4)P~2~ and PI(4,5)P~2~ {#sec4.4.7}

#### Sample Preparation {#sec4.4.7.1}

Lipids were extracted and derivatized with TMS-diazomethane; we added 2 M TMS-diazomethane in hexane (50 μl) to lipid extracts prepared as described above (approx I mL of 'lower phase'), to give a yellow solution, and then allowed the reaction to proceed for 10 min, RT. We quenched reactions with glacial acetic acid (6 μl), which removed the sample's yellow color (this reaction releases N~2~ gas, thus care should be taken). We added post-derivatisation wash solution (700 μl) to the organic solution, and mixed the samples, which we then centrifuged (5000 rpm, 3 min), and collected the resultant lower phase. We repeated the wash step, and then added MeOH:H~2~O (9:1 v:v, 100 μl) to the final collected lower phase. The samples were then dried down under a stream of nitrogen at room temperature without warming until dry. 160 μL methanol was then added and sonicated briefly, then left at RT for about 30 min prior to ozonolysis. A C-Lasky ozone generator was used in the following procedure. The unit was set to use air as the oxygen source at a flow rate of 4 dm^3^/min and the flow was split after the ozone generator so that approximately 75 to 90% of the flow went to an ozone destruction unit and the remaining fraction was used to bubble through the solution containing the samples. The power level on the ozone generator was set to about 60% of the maximum level. The Ozonolysis procedure started by placing the glass sample vials containing the methylated lipid solutions in an aluminum block which was cooled in an acetone/dry ice bath to a temperature of about −70°C. Ozone was then bubbled through the solutions for 5 min. Dimethyl sulphide (2 μl) was then added to each sample and then allowed to warm up to RT. Water (40 μl) was then added to each sample which was then ready to be submitted for analysis by UPLC, using the following conditions for PI(3,4P)2/PI(4,5P)2 separation:Solvent A: Water, 0.1% formic acidSolvent B: (40% acetonitrile/60% methanol), 0.1% formic acidColumn temperature: 60°CInjection volume 45 μl

Gradient:Time (min)Flow rate (mL/min)%A%BCurve00.4307018.990.43070619.000.42080122.000.42080624.000.40100629.000.40100630.000.43070635.000.430706

QTRAP4000 Mass spectrometer parameters:

Positive mode, Q1 and Q3 unit resolutionCUR20CADMediumIS4500DP100TEM300EP10GS118CE35GS220CXP10iheON

Turbo Spray source

Transitions:[AnalyteQ1 mass (Da)Q3 mass (Da)Dwell (ms)]{.ul}d6-SA-PIP~2~-Aldehyde product935.4445.350Endogenous SA PIP~2~-Aldehyde product929.4439.350Endogenous SA PI-Aldehyde product713.38439.35017:0-20:4 PI-Aldehyde product699.4425.350

### Measurement of PI3P and PI4P {#sec4.4.8}

Precisely the same conditions were used for the measurement of PI(3,4)P2 and PI(4,5)P2 described above, except for the following UPLC-MS condtions:

#### UPLC Conditions for PI3P/PI4P Separation {#sec4.4.8.1}

Additional sample preparation: Take 40 μl of sample prepared as above and add to 200μl 70% methanol /30% water. Inject 5 μlColumn: ACE Excel 2 C18-Amide, 150 mm x 0.5 mmSolvent A: Water, 0.1% formic acidSolvent B: (40% acetonitrile/60% methanol), 0.1% formic acidColumn temperature: 60°C

Gradient:Time (min)Flow rate (ul/min)%A%BCurve010307051030706101022781351022786361001006451001006461030706601030706

Mass spectrometer parameters as above.

Transitions:[AnalyteQ1 mass (Da)Q3 mass (Da)Dwell (ms)]{.ul}d6-SA-PIP-Aldehyde product827.4445.350

### \[33\]P-Pi Labeling of Mcf10a Cells {#sec4.4.9}

We added 0.1 mL of 1.5 M NaCl to 1 mL of \[33\]P-Pi and then diluted this mixture into a phosphate-depleted medium (GIBCO) and supplemented with (20 mM HEPES, 1% Dialysed FBS, 500 ng/mL hydrocortisone, 100 ng/mL cholera toxin) to reach a final concentration of 250 μC/mL. After siRNA transfection, as described above, cells were starved for 16 hr, then washed twice with phosphate-depleted medium before adding the \[33\]P-Pi--containing medium for 90 min. Then we stimulated the cells with 10 ng/mL hEGF. We aspirated the medium then stopped the reaction with ice-cold 1 M HCl. We extracted and deacylated the lipids, and analyzed the glycerophoinositides by strong anion-exchange chromatography ([@bib20]).

### In Vitro Phosphatase Assay {#sec4.4.10}

Mcf10a cells (1x10^6^) were seeded in 10 cm tissue culture dishes and grown for 64 hr, then washed twice with ice-cold PBS prior to lysis with 1 mL of lysis buffer (10 mM Tris pH7.4, 1.5 mM MgCl~2~, 5 mM KCl, 1 mM DTT, anti-proteases (1 tablet Roche inhibitor cocktail per 50 mL lysis buffer)) on ice. Cells were then scraped on ice, collected in 2 mL safe lock Eppendorf tubes, vortexed, and kept on ice for 5 min. The lysate was sonicated on ice (4 × 10 s; probe sonication) and then ultracentrifuged (40,000 x g for 30 min at 4°C). A 50 μL aliquot was taken for subsequent protein analysis and this, along with the remainder of the sample, were snap frozen in liquid N2 and stored at −80°C. Protein determination was performed on the 50 μL aliquots. The remainder of each sample was then thawed and all samples normalized to the same protein concentration with lysis buffer. The lysates were then divided into 100 μL aliquots and frozen at −80°C. For in-lysate phosphatase assays, a 100 μL aliquot was thawed on ice, then an aliquot containing 4 μg of protein was diluted to 20 μL with a solution containing 2 mg/mL of BSA, 160 mM KCl, 1 mM MgCl2, 20 mM HEPES pH7.3 and 1 mM EGTA. These 20 μL aliquots of cytosol were then used directly in the phosphatase assays, see below.

Micelles consisting of a mixture of lipids and a d6-phosphoinositide substrate were prepared at RT as follows. A lipid solution containing liver PI, brain PE, brain PC, brain PS, sphingomyelin, cholesterol, brain PI(4,5)P2 and either d6-C18:0/C20:4-PI(3,4)P2 or, d6- C18:0/C20:4-PI(3,4,5)P3, was prepared in a glass vial at 32.4:23.2:10.5:23.7:2.6:0.9:2.9:3.7 (w/w) ratio (all lipids in their respective solvents) and solvents evaporated under vacuum. In order to reconstitute the lyophilized lipid mixture into micelles, 200 μL of a solution containing 20 mM HEPES pH7.3, 0.1 mM EDTA and 1 mM EGTA was added and the lipid solution bath sonicated for 1 min and divided into 20 μL aliquots.

A 20 μL aliquot of diluted cell lysate was then added to 20 μL micellar solutions and incubated at 30°C for the indicated times. Reactions were terminated by the addition of 1 mL ice-cold 20% trichloroacetic acid (TCA), followed by centrifugation (13,000 x g, 5 min, 4°C) and a single wash with 5% TCA. Samples were then incubated on ice for 5 min, centrifuged (13,000 x g, 5 min, 4°C) and the supernatant aspirated. The resultant pellet was then processed for lipid analysis as described for cell pellets, see above.

### Invadopodia Assay {#sec4.4.11}

#### Slides and Cells Preparation {#sec4.4.11.1}

Prior to the experiment, 13 mm coverslips were pre-coated with gelatin enriched with fluorescently labeled Oregon Green 488 gelatin ([@bib41]). Mcf10a cells were grown for 6 days in complete medium supplemented with 10 ng/mL rhTGF-β1. 5x10^4^ cells were seeded in complete medium on the fluorescent gelatin surface and left to adhere (between 2-2.5 h). Next, cells were washed with PBS, starved for 4 hr, and then stimulated with 20 ng/mL hEGF for another 6 hr. Both complete and starvation media were supplemented with 10 ng/mL rhTGF-β1. After washing with PBS and fixing in 3.7% PFA (15 min at RT), cells were labeled for cortactin following a previously described protocol ([@bib19]) and the nuclei (Hoechst dye, 0.8 ng/mL added to a PBS wash).

#### Invadopodia Imaging and Data Analysis {#sec4.4.11.2}

In each experiment, 3 coverslips were prepared per condition. Fixed and labeled cells were imaged using a confocal Nikon A1R microscope with a 60x oil objective. 15 images were obtained per coverslip with an average of 15 cells per field of view. All cells were scored for the instances in which cortactin labeling aligned with a hole created in the gelatin and these were then normalized to the number of nuclei per field of view.

### Live Cell Imaging of Mcf10a Cells {#sec4.4.12}

Mcf10a cells expressing mCherry-PH-TAPP1 or GFP-PH-GRP1 were imaged by Spinning Disc Microscopy, z = 0.5uM at 37°C and 5% CO2, with a 100x objective.

### Mouse Prostate Dissection and Processing {#sec4.4.13}

Mice were sacrificed using Schedule 1 methods, in agreement with the Animals (Scientific Procedures) Act 1986 (ASPA) and tissues rapidly dissected. Prostates, consisting of anterior, ventral, and dorsolateral lobes (one pair of each lobe), were dissected intact and one set of anterior, dorsolateral, and ventral lobes was used for western blot, while the other set was used for IHC. For western blot and measurements of phosphoinositides, tissues were rinsed in PBS and flash-frozen in N~2(l)~. For IHC, prostates were rinsed in PBS and fixed in 4% paraformaldehyde for 1 hr at room temperature. Prostates were then cryo-protected by immersion in 30% w/v sucrose in PBS, while rotating at 4°C, for 1 hr for WT prostates, and for 2-3 hr for PTEN-KO prostates. Prostates were then immersed in embedding medium and slowly frozen on dry ice. Embedded prostates were stored at −80°C until use. 12 μm cryosections were prepared on charged glass slides using a Leica CM1850 cryostat. INPP4B-KO and PTEN-INPP4B-KO prostates were dissected intact and prepared for measurements of phosphoinositides or for immunofluorescence on site at Akita University.

### Mouse Prostate Imaging {#sec4.4.14}

#### H&E Staining {#sec4.4.14.1}

H&E staining of prostate cryosections prepared on glass slides was performed using Mayer's hematoxylin and Eosin Y solutions, following a standard protocol. Images were acquired using a Zeiss Laser Microdissection microscope (20x or 40x air objectives), stitched with AxioVision4 software (5% overlap) and gaps automatically filled with Adobe Photoshop. Alternatively, an Olympus BX41 microscope equipped with a 40x oil objective was used to obtain higher resolution images. These were then manually stitched using Velocity software with a brightness correction.

#### Immunofluorescence {#sec4.4.14.2}

12 μm mouse prostate cryosections prepared on glass slides were stained for PI(3,4)P2 by permeabilising the sections with saponin (30 min at RT in 0.5% saponin, 1% BSA in PBS). Cells were labeled with the anti-PI(3,4)P2 antibody at 1:150 dilution for 2 hr at room temperature, then sections were washed 3 times with PBS and incubated with streptavidin-Alexa Fluor 674 for 1 hr at room temperature, in a humid dark room. In some experiments, an additional incubation with anti-phospho-Akt-S473 antibody was carried out according to the manufacturer's instructions (Cell Signaling Technologies). After having washed the sections three times with PBS, sections were incubated in PBS supplemented with Hoechst dye for 10 min; after 3 washes with PBS, sections were then mounted with a hard-set medium. Sections were imaged with a wide field Nikon Live Cell Imager microscope and 20x air objective. Multiple fields of view were stitched automatically with 10% overlap using NIS-Elements software integrated with the microscope.

### HPLC-MS Measurement of Mouse Prostate Phophoinositides {#sec4.4.15}

Unpublished work from our laboratories had indicated that the most predominant molecular species of PI(3,4,5)P3 and PI(3,4)P2 which accumulate in mouse prostate on deletion of PTEN were the shorter chain, more saturated species. We therefore used a new HPCL-MS method (manuscript in preparation) to analyze 17 different species of phosphoinositides in this tissue and present results for the combined total of all species measured (C32:0; C32:1; C34:0; C34:1; C34:2; C36:0; C36:1; C36:2, C36:3; C36:4; C38:3; C38:4; C38:5; C38:6; C40:4; C40;5; C40:6). Data were corrected for wet weight of tissue. At least three individual mice were used per genotype.

### Mathematical Modeling {#sec4.4.16}

A range of mathematical models were built and analyzed in COPASI ([@bib27]). The models included the activation of EGFR by EGF, its effect on Class I PI3K activity, the phosphorylation and dephosphorylation PI(4,5)P2, PI(3,4)P2 and PI(3,4,5)P3. Reactions were modeled using mass-action or Michaelis-Menten kinetics (see [Data S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, and [S3](#mmc4){ref-type="supplementary-material"}). PI-103 inhibition was represented as affecting the concentration of effective PI3K, while knockdown and knockout were implemented as modifications of rate constants for the corresponding enzymes. The final model was parameterized using all the available datasets, using a genetic algorithm. The complete model is provided in the COPASI format as [Data S1](#mmc2){ref-type="supplementary-material"}, and in the standard format SBML ([@bib28]) as [Data S2](#mmc3){ref-type="supplementary-material"}. The accession number for the mathematical model created in this manuscript is BioModels: MODEL1704190000 ([@bib37]).

### Statistics {#sec4.4.17}

Unless stated otherwise, data are means ± SEM of at least three biological replicates, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.005, and ^∗∗∗∗^p \< 0.0001. For the invadopodia assay in Mcf10a clones ([Figure 6](#fig6){ref-type="fig"}D), Tukey's multiple comparisons test was used (with p values of p \< 0.05, p \< 0.01, p \< 0.001 and p \< 0.0001 corresponding to 1-4 stars on the graph).

### Experimental Design {#sec4.4.18}

A strategy for randomization, stratification or blind selection of samples has not been carried out. Sample sizes were not chosen based on pre-specified effect size. Instead, multiple independent experiments were carried out using several sample replicates as detailed in the figure legends.
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